Acacia Research Corporation (Nasdaq:ACTG) announced today that a subsidiary has acquired rights to a patent portfolio for prescription lens technology.
“Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios”
"As Acacia's licensing success grows, an increasing number of technology companies are selecting us as their partner for the licensing of their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios," concluded Mr. Ryan.
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates